Zika Hearing Shows How Vaccine Timelines Are Outbreak-Dependent
This article was originally published in The Pink Sheet Daily
NIAID appears on track to have Zika vaccine in widespread testing in late 2017, but development depends in part on the epidemic rate; additional funding is necessary to respond to the outbreak, NIAID director and CDC official testify at Senate and House hearings.
You may also be interested in...
Nothing's even in Phase II yet, but sponsors and US government researchers remain optimistic.
FDA and NIH officials propose three strategies for clinical trials, saying it will be challenging to identify the most promising candidates; Sanofi and Walter Reed researchers note challenges in vaccine development, including manufacturing scale up.
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.